Tarsus Pharmaceuticals(TARS) ZACKS·2024-12-04 15:56Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) shows potential for further upside, with a mean price target of 50.40, following a 10.4% gain over the past four weeks [1]. Price Target Analysis - The average price target consists of eight estimates ranging from a low of 84, with a standard deviation of $12.83, indicating variability among analysts [2]. - The lowest estimate suggests an 18.7% decline, while the highest indicates a 66.7% upside, highlighting the range of opinions among analysts [2]. Analyst Sentiment - Analysts exhibit strong agreement on TARS's ability to report better earnings than previously predicted, which supports the expectation of an upside [4]. - A positive trend in earnings estimate revisions has been shown to correlate with stock price movements, reinforcing the potential for TARS's stock to rise [9]. Earnings Estimates - Over the last 30 days, six earnings estimates for TARS have been revised upward, with no negative revisions, leading to a 13.4% increase in the Zacks Consensus Estimate [10]. - TARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of TARS's price movement, the direction implied by the targets appears to be a useful guide for investors [12].